Genomic Testing Cooperative lca (GTC) and TherapySelect have agreed to collaborate regarding the offer to the EU market of GTC's leading edge next generation sequencing (NGS) diagnostic tests.
Since May, 8th TherapySelect acts as authorized representative and importer for the European' Union for the following NGS diagnostics tests provided by GTC:
- Solid Tumor Profile Plus
(comprehensive DNA and RNA analyses done with FFPE (formalin-fixed, paraffin embedded) blocks for patients with solid tumors)
- Liquid Biopsy Solid Tumor Profile
(comprehensive DNA analysis done with blood samples for patients with solid tumors)
- Hematology Profile Plus
(comprehensive DNA and RNA analyses done with blood samples, bone marrow, fresh tissue or FFPE samples for patients with hematological tumors)
- Liquid Biopsy Hematology Profile
(comprehensive DNA done with blood samples for patients with hematological tumors)
This exciting collaboration enables TherapySelect to offer GTC's leading edge NGS services to all our customers.
Solid Tumor Profile Plus, Liquid Biopsy Solid Tumor Profile, Hematology Profile Plus, Liquid Biopsy Hematology Profile are CE certified in vitro diagnostic medical devices in conformity with Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices.
The tests are available now and can be ordered by physicians and patients. Please contact TherapySelect for product, pricing and ordering inquiries.
Our website will be updated with further detail on these new services in the near future, but in the meantime if you have any immediate queries please do not hesitate to get in contact.